TBRG (TruBridge, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TBRG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Regina M. Benjamin | Director | D | — | — |
| 2026-07-10 | L6 Holdings Inc. | 10%+ Owner | U | — | — |
| 2026-07-10 | Mark V Anquillare | Director | D | — | — |
| 2026-07-10 | DAVID A DYE | Director | MIXED | — | — |
| 2026-07-10 | CHRISTOPHER T HJELM | Director | D | — | — |
| 2026-07-10 | Damien Leonard | Director | D | — | — |
| 2026-07-10 | Christopher L Fowler | President and CEO | D | — | — |
| 2026-07-10 | Kevin Plessner | General Counsel | D | — | — |
| 2026-07-10 | Andris Upitis | Director | D | — | — |
| 2026-07-10 | David Harse | General Manager Patient Care | D | — | — |
| 2026-07-10 | Vita MacIntyre | Controller | D | — | — |
| 2026-07-10 | GLENN TOBIN | Director | D | — | — |
| 2026-07-10 | Michael Daughton | Chief Business Officer | D | — | — |
| 2026-07-10 | Vinay Bassi | Chief Financial Officer | D | — | — |
| 2026-07-10 | Merideth Wilson | Financial Health GM | D | — | — |
| 2026-07-10 | Amy K O'Keefe | Director | D | — | — |
| 2026-07-10 | Jerry G Canada Jr. | Director | D | — | — |
| 2026-04-09 | Kevin Plessner | General Counsel | A | — | — |
| 2026-04-09 | Vita MacIntyre | Controller | A | — | — |
| 2026-04-09 | Christopher L Fowler | President and CEO | A | — | — |
| 2026-04-09 | David Harse | General Manager Patient Care | A | — | — |
| 2026-04-09 | Vinay Bassi | Chief Financial Officer | A | — | — |
| 2026-04-09 | Merideth Wilson | Financial Health GM | A | — | — |
| 2026-04-09 | Michael Daughton | Chief Business Officer | A | — | — |
| 2026-03-30 | Vita MacIntyre | Controller | F | — | — |
| 2026-03-17 | Vita MacIntyre | Controller | F | — | — |
| 2026-03-17 | Merideth Wilson | Financial Health GM | F | — | — |
| 2026-03-17 | David Harse | General Manager Patient Care | F | — | — |
| 2026-03-17 | Vinay Bassi | Chief Financial Officer | F | — | — |
| 2026-03-17 | Kevin Plessner | General Counsel | F | — | — |
| 2026-03-17 | Christopher L Fowler | President and CEO | F | — | — |
| 2026-03-17 | DAVID A DYE | Director | F | — | — |
| 2026-03-11 | Kevin Plessner | General Counsel | F | — | — |
| 2026-03-11 | Christopher L Fowler | President and CEO | F | — | — |
| 2026-03-11 | DAVID A DYE | Director | MIXED | — | — |
| 2026-03-11 | David Harse | General Manager Patient Care | F | — | — |
| 2025-12-03 | Pinetree Capital Ltd. | 10%+ Owner | Buy | — | — |
| 2025-11-20 | L6 Holdings Inc. | 10%+ Owner | Buy | — | — |
| 2025-11-19 | L6 Holdings Inc. | 10%+ Owner | Buy | — | — |
| 2025-11-18 | Michael Daughton | Chief Business Officer | Buy | — | — |
| 2025-11-14 | Pinetree Capital Ltd. | 10%+ Owner | Buy | — | — |
| 2025-10-15 | Michael Daughton | Chief Business Officer | A | — | — |
| 2025-08-15 | David Harse | General Manager Patient Care | Sell | — | — |
| 2025-07-28 | Vita MacIntyre | Controller | Sell | — | — |
| 2025-07-03 | Christopher L Fowler | President and CEO | F | — | — |
| 2025-05-23 | L6 Holdings Inc. | 10%+ Owner | Buy | — | — |
| 2025-05-23 | L6 Holdings Inc. | 10%+ Owner | Buy | — | — |
| 2025-05-20 | Christopher L Fowler | President and CEO | Sell | — | — |
| 2025-03-31 | Vita MacIntyre | Controller | F | — | — |
| 2025-03-26 | Merideth Wilson | Financial Health GM | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,075,000 | — |
| — | President and CEO | 120,486 | — |
| — | Chief Operating Officer | 81,646 | — |
| — | Chief Business Officer | 59,315 | — |
| — | Chief Technology & Innovation | 40,717 | — |
| — | Chief Financial Officer | 39,992 | — |
| — | Director | 34,311 | — |
| — | Chief Sales Officer | 30,595 | — |
| — | General Manager Patient Care | 16,888 | — |
| — | VP Finance & Controller | 13,052 | — |
| — | General Counsel | 12,460 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TBRG quote page; the site-wide leaderboard is on the insider transactions hub.